The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support Amvuttra’s Phase 3 HELIOS-B trial The transaction excludes ...
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by ...
NEW YORK/CAMBRIDGE - Royalty Pharma plc (NASDAQ:RPRX) has purchased a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences for $310 million, according to a press release statement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results